Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, THERAVANCE BIOPHARMA, INC. reported revenue of $107M, up 66.9% year over year. Operating margin was -3.4% and net margin 98.5%, on a free-cash-flow margin of 221.9% with capital expenditure at 0.0% of revenue. Every figure is computed directly from TBPH's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $107M | -3.4% | 98.5% |
| FY2024 | $64M | -72.9% | -87.6% |
| FY2023 | $57M | -97.6% | -96.1% |
| FY2022 | $51M | -179.1% | 1698.5% |
| FY2021 | $55M | -466.1% | -360.6% |
How does TBPH compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.